Profile change history

What changed for Goserelin?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Goserelin identity.

64Total events
64Record additions
0Version changes
17Cited source years

Collection chronology

Evidence added to PeptideScanner

Browse all 64 connected records →

Showing the latest 64 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 15, 2026.

Record added

ClinicalTrials.gov record NCT00004124

PeptideScanner retained ClinicalTrials.gov record NCT00004124 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-12-30, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
December 30, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00005044

PeptideScanner retained ClinicalTrials.gov record NCT00005044 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-06-15, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
June 15, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00108732

PeptideScanner retained ClinicalTrials.gov record NCT00108732 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-06-30, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
June 30, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00114114

PeptideScanner retained ClinicalTrials.gov record NCT00114114 at 2026-11-15T21:50:32.222Z. Its registry update date was 2019-10-08, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
October 8, 2019
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00186121

PeptideScanner retained ClinicalTrials.gov record NCT00186121 at 2026-11-15T21:50:32.222Z. Its registry update date was 2019-10-07, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
October 7, 2019
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00283803

PeptideScanner retained ClinicalTrials.gov record NCT00283803 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
August 7, 2018
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00295646

PeptideScanner retained ClinicalTrials.gov record NCT00295646 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-15, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
March 15, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00322348

PeptideScanner retained ClinicalTrials.gov record NCT00322348 at 2026-11-15T21:50:32.222Z. Its registry update date was 2011-01-24, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
January 24, 2011
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00328614

PeptideScanner retained ClinicalTrials.gov record NCT00328614 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-05-16, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
May 16, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00432172

PeptideScanner retained ClinicalTrials.gov record NCT00432172 at 2026-11-15T21:50:32.222Z. Its registry update date was 2023-04-03, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
April 3, 2023
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00586898

PeptideScanner retained ClinicalTrials.gov record NCT00586898 at 2026-11-15T21:50:32.222Z. Its registry update date was 2016-03-25, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
March 25, 2016
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00605267

PeptideScanner retained ClinicalTrials.gov record NCT00605267 at 2026-11-15T21:50:32.222Z. Its registry update date was 2012-09-06, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
September 6, 2012
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01073865

PeptideScanner retained ClinicalTrials.gov record NCT01073865 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-12-12, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
December 12, 2018
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01250717

PeptideScanner retained ClinicalTrials.gov record NCT01250717 at 2026-11-15T21:50:32.222Z. Its registry update date was 2014-02-04, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
February 4, 2014
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01496131

PeptideScanner retained ClinicalTrials.gov record NCT01496131 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-03-09, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
March 9, 2018
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01682642

PeptideScanner retained ClinicalTrials.gov record NCT01682642 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-03-20, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
March 20, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01723774

PeptideScanner retained ClinicalTrials.gov record NCT01723774 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
September 25, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02003209

PeptideScanner retained ClinicalTrials.gov record NCT02003209 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
October 6, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02115282

PeptideScanner retained ClinicalTrials.gov record NCT02115282 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
October 22, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02278120

PeptideScanner retained ClinicalTrials.gov record NCT02278120 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-12, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
March 12, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02430480

PeptideScanner retained ClinicalTrials.gov record NCT02430480 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
July 16, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02518191

PeptideScanner retained ClinicalTrials.gov record NCT02518191 at 2026-11-15T21:50:32.222Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
June 11, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02586675

PeptideScanner retained ClinicalTrials.gov record NCT02586675 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-01-21, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
January 21, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03007979

PeptideScanner retained ClinicalTrials.gov record NCT03007979 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-20, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
March 20, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03096847

PeptideScanner retained ClinicalTrials.gov record NCT03096847 at 2026-11-15T21:50:32.222Z. Its registry update date was 2021-10-11, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
October 11, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03671330

PeptideScanner retained ClinicalTrials.gov record NCT03671330 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
July 8, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03822468

PeptideScanner retained ClinicalTrials.gov record NCT03822468 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-10-16, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
October 16, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03839823

PeptideScanner retained ClinicalTrials.gov record NCT03839823 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-10-09, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
October 9, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05161195

PeptideScanner retained ClinicalTrials.gov record NCT05161195 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
October 19, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07310420

PeptideScanner retained ClinicalTrials.gov record NCT07310420 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

Federal Register notice 2022-25210

The Federal Register published notice 2022-25210, attributed to FDA and its parent HHS department, on 2022-11-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon and Goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
November 18, 2022
Evidence lane
Regulatory
Record added

Federal Register notice 97-10911

The Federal Register published notice 97-10911, attributed to FDA and its parent HHS department, on 1997-04-28. Its official title is “Environmental Assessments and Findings of No Significant Impact,” and PeptideScanner's exact reviewed identity mapping connects the document to Goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
April 28, 1997
Evidence lane
Regulatory
Record added

Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy.

PubMed lists PMID 12183859 in The Israel Medical Association journal : IMAJ as Clinical Trial, Journal Article, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study.

PubMed lists PMID 12217302 in European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 6, 2019
Evidence lane
Literature metadata
Record added

Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

PubMed lists PMID 12477997 in American journal of clinical oncology as Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 2002-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
September 6, 2019
Evidence lane
Literature metadata
Record added

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patien…

PubMed lists PMID 12488405 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2002-12-15 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 2, 2016
Evidence lane
Literature metadata
Record added

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

PubMed lists PMID 14530912 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2003-10-03 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 13, 2018
Evidence lane
Literature metadata
Record added

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

PubMed lists PMID 14679153 in Journal of the National Cancer Institute as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, and 1 more PubMed publication type, with publication-date metadata of 2003-12-17 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
March 31, 2022
Evidence lane
Literature metadata
Record added

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

PubMed lists PMID 14760369 in British journal of cancer as Clinical Trial, Journal Article, with publication-date metadata of 2004-02-09 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
March 9, 2022
Evidence lane
Literature metadata
Record added

Goserelin ('Zoladex')--offering patients more choice in early breast cancer.

PubMed lists PMID 15590321 in European journal of oncology nursing : the official journal of European Oncology Nursing Society as Journal Article, Review, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
January 28, 2026
Evidence lane
Literature metadata
Record added

European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia.

PubMed lists PMID 15592276 in American journal of obstetrics and gynecology as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.

PubMed lists PMID 15668708 in British journal of cancer as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2005-02-14 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
August 21, 2024
Evidence lane
Literature metadata
Record added

Use of goserelin in the treatment of breast cancer.

PubMed lists PMID 16111461 in Expert review of anticancer therapy as Journal Article, Review, with publication-date metadata of 2005-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer.

PubMed lists PMID 16222310 in British journal of cancer as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2005-09-19 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
March 16, 2022
Evidence lane
Literature metadata
Record added

[Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B].

PubMed lists PMID 16352931 in Gan to kagaku ryoho. Cancer & chemotherapy as English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2005-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.

PubMed lists PMID 16392882 in Drugs as Journal Article, Review, with publication-date metadata of 2005 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 13, 2018
Evidence lane
Literature metadata
Record added

[Hysteroresection of submucous myomas after treatment with zoladex].

PubMed lists PMID 16637313 in Akusherstvo i ginekologiia as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).

PubMed lists PMID 16765589 in European journal of cancer (Oxford, England : 1990) as Clinical Trial, Phase IV, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006-06-12 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

[Using GnRH-agonists (Zoladex) in the treatment of genital endometriosis].

PubMed lists PMID 16889194 in Akusherstvo i ginekologiia as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

Goserelin acetate in combination with radiotherapy for prostate cancer.

PubMed lists PMID 17257094 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-02 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
September 17, 2019
Evidence lane
Literature metadata
Record added

Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.

PubMed lists PMID 20679610 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-08-02 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
March 31, 2022
Evidence lane
Literature metadata
Record added

A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer.

PubMed lists PMID 21380781 in Medical oncology (Northwood, London, England) as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2011-03-06 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
January 28, 2026
Evidence lane
Literature metadata
Record added

Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.

PubMed lists PMID 21625929 in Breast cancer research and treatment as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-05-29 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
April 28, 2025
Evidence lane
Literature metadata
Record added

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

PubMed lists PMID 22265697 in The Lancet. Oncology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-01-20 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
January 28, 2026
Evidence lane
Literature metadata
Record added

Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.

PubMed lists PMID 22674191 in The Prostate as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-06-05 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 20, 2014
Evidence lane
Literature metadata
Record added

Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.

PubMed lists PMID 22972694 in Cancer as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-09-12 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
March 9, 2022
Evidence lane
Literature metadata
Record added

Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.

PubMed lists PMID 23184499 in Breast cancer (Tokyo, Japan) as Clinical Trial, Journal Article, with publication-date metadata of 2012-11-25 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
January 28, 2026
Evidence lane
Literature metadata
Record added

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer.

PubMed lists PMID 26131799 in Medicine as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2015-07 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
March 5, 2026
Evidence lane
Literature metadata
Record added

Erythema nodosum caused by goserelin acetate sustained-release: Case report and literature review.

PubMed lists PMID 37114900 in International journal of rheumatic diseases as Review, Case Reports, Journal Article, with publication-date metadata of 2023-04-28 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
October 10, 2023
Evidence lane
Literature metadata
Record added

Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU.

PubMed lists PMID 38940667 in Clinical cancer research : an official journal of the American Association for Cancer Research as Journal Article, Clinical Trial, Phase II, Multicenter Study, with publication-date metadata of 2024-08-15 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
February 7, 2025
Evidence lane
Literature metadata
Record added

[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer].

PubMed lists PMID 40268551 in Zhonghua zhong liu za zhi [Chinese journal of oncology] as Journal Article, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Comparative Study, and 1 more PubMed publication type, with publication-date metadata of 2025-04-23 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
May 27, 2025
Evidence lane
Literature metadata
Record added

Roles of Goserelin in Gynecological Disorders.

PubMed lists PMID 42226753 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2026-05-27 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
August 13, 2026
Evidence lane
Literature metadata